AlzeCure Pharma – executive interview

Published on 24 March 2021

AlzeCure Pharma is a clinical-stage biotech company based in Sweden, focused on developing its pipeline of small molecule drugs for the treatment of Alzheimer’s disease (symptomatic and disease modifying) and pain (neuropathic and osteoarthritic). It recently initiated two Phase I trials, one for ACD856, which is being developed as a symptomatic treatment for the Alzheimer’s disease, and another for ACD440, a topical treatment for neuropathic pain.

In this video, Martin Jönsson, AlzeCure’s chief executive officer, provides an overview of the pipeline and outlines newsflow expected in the year ahead.

Share this with friends and colleagues